HKSE - Delayed Quote ? HKD
Clover Biopharmaceuticals, Ltd. (2197.HK)
At close: 4:08 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
39,255.000
39,255.000
--
--
--
Cost of Revenue
15,014.000
15,014.000
--
--
--
Gross Profit
24,241.000
24,241.000
--
--
--
Operating Expense
896,331.000
896,331.000
1,861,152.000
2,157,785.000
284,289.000
Operating Income
-872,090.000
-872,090.000
-1,861,152.000
-2,157,785.000
-284,289.000
Net Non Operating Interest Income Expense
-2,605.000
-2,605.000
2,577.000
2,674.000
435.000
Pretax Income
-138,539.000
-138,539.000
-2,451,903.000
-6,016,303.000
-912,898.000
Net Income Common Stockholders
-138,539.000
-138,539.000
-2,451,903.000
-6,016,303.000
-912,898.000
Diluted NI Available to Com Stockholders
-138,539.000
-138,539.000
-2,451,903.000
-6,016,303.000
-912,898.000
Basic EPS
-0.65
-0.11
-2.22
-13.02
-0.79
Diluted EPS
-0.65
-0.11
-2.22
-13.02
-0.79
Basic Average Shares
1,179,166.490
1,243,504.146
1,102,103.513
462,117.327
1,158,114.723
Diluted Average Shares
1,182,010.185
1,243,504.146
1,102,103.513
462,117.327
1,158,114.723
Total Expenses
911,345.000
911,345.000
1,861,152.000
2,157,785.000
284,289.000
Net Income from Continuing & Discontinued Operation
-138,539.000
-138,539.000
-2,451,903.000
-6,016,303.000
-912,898.000
Normalized Income
1,621,636.000
1,621,636.000
-1,898,741.000
-6,017,211.000
-912,898.000
Interest Income
16,118.000
16,118.000
8,507.000
10,890.000
3,408.000
Interest Expense
18,723.000
18,723.000
5,930.000
2,520.000
1,657.000
Net Interest Income
-2,605.000
-2,605.000
2,577.000
2,674.000
435.000
EBIT
-119,816.000
-119,816.000
-2,445,973.000
-6,013,783.000
-911,241.000
EBITDA
-45,074.000
-45,074.000
-2,385,879.000
-5,988,394.000
-905,457.000
Reconciled Cost of Revenue
15,014.000
15,014.000
--
--
--
Reconciled Depreciation
74,742.000
74,742.000
60,094.000
25,389.000
5,784.000
Net Income from Continuing Operation Net Minority Interest
-138,539.000
-138,539.000
-2,451,903.000
-6,016,303.000
-912,898.000
Total Unusual Items Excluding Goodwill
-1,760,175.000
-1,760,175.000
-553,162.000
908.000
--
Total Unusual Items
-1,760,175.000
-1,760,175.000
-553,162.000
908.000
--
Normalized EBITDA
1,715,101.000
1,715,101.000
-1,832,717.000
-5,989,302.000
-905,457.000
12/31/2020 - 11/5/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2157.HK Lepu Biopharma Co., Ltd.
2.740
+0.74%
9966.HK Alphamab Oncology
2.280
-3.39%
6660.HK AIM Vaccine Co., Ltd.
4.280
-2.28%
2105.HK Laekna, Inc.
4.850
+0.62%
9995.HK RemeGen Co., Ltd.
12.460
+2.47%
9688.HK Zai Lab Limited
15.680
+4.53%
1877.HK Shanghai Junshi Biosciences Co., Ltd.
10.700
+0.56%
688062.SS Mabwell (Shanghai) Bioscience Co., Ltd.
24.00
+3.90%
688382.SS InventisBio Co., Limited
7.33
+1.52%
2181.HK Mabpharm Limited
0.350
-1.41%